Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birtamimab Plus Standard of Care vs Placebo in Mayo Stage IV AL Amyloidosis
2024-511066-36-00Phase 3Completed
- Sponsor
- Prothena Corporation
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing Birtamimab plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Time to all-cause mortality. Started Nov 2024; status: completed.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2024-511066-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511066-36-00.